Mucocutaneous Paraneoplastic Syndromes Associated With Hematologic Malignancies Cancer Network Treatment guidelines are not available, but case series point to the use of rituximab (Rituxan) as well as corticosteroids and various other immunomodulating agents. Here we present a diagnostic and treatment dilemma in a 39-year-old active-duty male ... |
